Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PHARMACEUTICALS INC / MA

Form 4 May 15, 2008

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

OMB Number:

Check this box if no longer STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to **SECURITIES** Section 16. Form 4 or

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

Form 5

obligations

(Print or Type Responses)

1. Name and Address of Reporting Person *

SMITH IAN F

2. Issuer Name and Ticker or Trading

Symbol

(Middle)

VERTEX PHARMACEUTICALS

INC / MA [VRTX]

3. Date of Earliest Transaction

05/13/2008

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

(Last) (First)

(Month/Day/Year)

Director X_ Officer (give title

10% Owner Other (specify

OMB APPROVAL

Estimated average

burden hours per

Expires:

response...

3235-0287

January 31,

2005

0.5

below) **EVP & CFO**

C/O VERTEX **PHARMACEUTICALS**

INCORPORATED, 130 WAVERLY

05/13/2008

05/13/2008

STREET

Common

Common

Stock

Stock

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

D

D

89,431

89,281

CAMBRIDGE, MA 02139

							Person				
(City)	(State)	(Zip) Table	e I - Non-D	erivative	ities Acq	equired, Disposed of, or Beneficially Ow					
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securi n(A) or Di (Instr. 3,	ispose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock	05/13/2008		S(1)	50	D	\$ 26.99	89,981	D			
Common Stock	05/13/2008		S(1)	475	D	\$ 27	89,506	D			

75

150

D

D

 $S^{(1)}$

 $S^{(1)}$

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Con	nmon ck	05/13/2008	S <u>(1)</u>	580	D	\$ 27.11	88,701	D	
Con	nmon ek	05/13/2008	S(1)	70	D	\$ 27.2	88,631	D	
Con	nmon ek	05/13/2008	S(1)	50	D	\$ 27.26	88,581	D	
Con	nmon ek	05/13/2008	S(1)	100	D	\$ 27.46	88,481	D	
Con	nmon ek	05/13/2008	S(1)	80	D	\$ 27.7	88,401	D	
Con Stoc	nmon ck	05/13/2008	S <u>(1)</u>	400	D	\$ 27.01	88,001	D	
Con Stoc	nmon ck	05/13/2008	S <u>(1)</u>	200	D	\$ 27.02	87,801	D	
Con	nmon ek	05/13/2008	S(1)	400	D	\$ 27.04	87,401	D	
Con	nmon ek	05/13/2008	S(1)	500	D	\$ 27.05	86,901	D	
Con Stoc	nmon ek	05/13/2008	S(1)	300	D	\$ 27.09	86,601	D	
Con	nmon ck	05/13/2008	S <u>(1)</u>	478	D	\$ 27.1	86,123	D	
Con	nmon ek	05/13/2008	S(1)	300	D	\$ 27.1	85,823	D	
Con	nmon ek	05/13/2008	S(1)	500	D	\$ 27.15	85,323	D	
Con	nmon ek	05/13/2008	S(1)	200	D	\$ 27.16	85,123	D	
Con	nmon ck	05/13/2008	S(1)	322	D	\$ 27.19	84,801	D	
Con	nmon ck	05/13/2008	S <u>(1)</u>	500	D	\$ 27.41	84,301	D	
Con	nmon ek						3,987	I	401(k)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

 $\label{thm:convergence} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (e.g., puts, calls, warrants, options, convertible securities) \end{tabular}$

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

1. Title of Derivative	2. Conversion	3. Transaction Date (Month/Day/Year)		4. Transaction	5. orNumber	6. Date Exerc Expiration D		7. Title a		8. Price of Derivative	9. Nu Deriv
Security (Instr. 3)	or Exercise Price of Derivative Security	(any (Month/Day/Year)	Code (Instr. 8)	of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/		Underlying Securities (Instr. 3 and 4)		Security (Instr. 5)	Secur Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title N	lumber		

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

SMITH IAN F C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE, MA 02139

EVP & CFO

Signatures

Valerie L. Andrews, Attorney-In-Fact 05/15/2008

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Smith's company approved trading plan established under Rule 10b5-1.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3